Oncology Drugs

Rakovina Therapeutics reports a dramatic financial recovery, slashing costs while boosting AI-driven R&D, positioning its promising cancer pipeline for growth.

Early Phase 1 data for APR-1051 reveals anti-tumor activity and manageable safety, offering a new glimmer of hope for patients with advanced solid tumors.

A new drug targeting cancer's 'immortality switch' enters a pivotal trial, offering hope for non-small cell lung cancer patients out of options.

A new drug combination delays cancer progression by over a year in advanced prostate cancer, offering new hope against treatment resistance, a new study finds.

Landmark Phase 3 trial shows TECVAYLI dramatically improves survival in early relapse, poised to become a new standard of care for multiple myeloma.

Celebrating two decades of innovation, RadioMedix unveils promising new alpha therapy data for pancreatic cancer at the SNMMI 2026 annual meeting.

A novel oncolytic bacteria therapy gains key approvals in the US and China, showcasing a new global development model enabled by CDMO Porton Advanced.

A novel drug aims to starve deadly brain tumors by rewiring their metabolism. BPGbio's upcoming ASCO update could signal a major shift for glioblastoma.

ZYUS secures high-interest debt to stay afloat, but a trading halt and unresolved accounting issues raise serious questions about its long-term resilience.

EOM Pharmaceutical gets FDA clearance for a trial on EOM613, a potential first-in-class treatment for cancer cachexia, a severe wasting syndrome.

NEOK Bio begins Phase 1 trials for two bispecific ADCs, a next-gen therapy aiming to outsmart tumor resistance and offer new hope for solid tumor patients.

New preclinical data shows RTY-406 could be a first-in-class therapy for PSC, a progressive liver disease with no effective treatments.

A new partnership between TD2 Oncology and Panome Bio aims to merge clinical expertise with deep multi-omics data to accelerate personalized cancer therapies.

Vanda Pharmaceuticals' rare disease drug gets a key designation in Japan, unlocking major incentives and promising a new treatment for a severe skin disease.

With CHF 105 million in new funding, NUCLIDIUM is advancing its novel copper-based radiotheranostics for metastatic prostate and breast cancer.

This year's Shaw Prize honors scientists who turned a deadly leukemia into a curable disease and unraveled the secrets of stellar explosions.

John Theurer Cancer Center presents breakthroughs in CAR-T, ADCs, and health equity at ASCO, offering new hope for patients worldwide.

Ionetix wins FDA approval for its generic prostate cancer imaging agent, a move set to boost access and shake up the competitive radiopharmaceutical market.

With new funding from Bregal Sagemount, LSPedia is set to advance its AI tools, moving beyond compliance to build a smarter, safer pharma supply chain.

A new global repository by Zifo and the Pistoia Alliance aims to standardize biological data, promising to accelerate drug discovery and fix costly data silos.